We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues
BusinessTechnology

Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues

HerinaAyot
HerinaAyot
Share
4 Min Read
SHARE

The US market represents huge profit potential for an innovative company, but not if unexpected FDA issues impede the launch, or reimbursement issues and adverse patent actions interfere with the success of the product.

The US market represents huge profit potential for an innovative company, but not if unexpected FDA issues impede the launch, or reimbursement issues and adverse patent actions interfere with the success of the product.

Recent studies have indicated that the time to gain approval is dramatically different between a CE Mark in Europe and a 510K in the United States. The time it takes to get a product to market takes on average, 6 months in Europe, compared to 2 years in the US, but, there is no evidence that suggests products in Europe are not safe. Increasingly, companies are launching in Europe while waiting for approval in the United States. A special morning panel at OneMedForum NY 2011 will explore the merits of this strategy in terms of creating capital efficiency. It will consider other strategic planning considerations in the process of getting approval and reimbursement.

The morning session will explore the implications of this for emerging companies and investors and will focus on a case study of how to get approval,  considering both Europe  and the United States.

More Read

2012 Medicare Physician Fee Schedule Final Rule Important for Telemedicine
Wireless Devices Will Dramatically Change How Medicine Is Practiced
Cleveland Clinic’s Latest Startup Tackles Hospital-Patient Communication and Scheduling
7 Useful Tips: How to Engage and Inspire Action and Social Sharing
Do Overworked Medical Interns Cause Medical Errors? Let’s Sleep on It.

Panelists include: Rod Barnes, former VP Reimbursement at Alcon Lab;  Rosina Robinson, RN, MEd, RAC, MDCI; Richard Naples, Sr. Vice President, Regulatory Affairs, Becton Dickinson; and Corinne Lebourgeois, Med C Partners .

Corinne Lebourgeois notes that reimbursement in Europe is very fragmented with healthcare and funding varying from country to country. She aims to dissect this issue and bring knowledge of navigating the  reimbursement process to the forefront.  While Europe is and will remain for the coming decade at least, the second-largest market for medical devices worldwide, with approximately 33 percent of global sales taking place there, it’s complexity is high. Although the European Union tries to harmonize its different regulatory systems, in practice many differences still exist in the application of reimbursement systems. These include a number of institutions involved in the whole process in a given country, the application time, and the number of product classes defined.

In today’s environment, payers are increasingly sophisticated and rely more and more upon specific clinical evidence and health economic data to drive the reimbursement process. This makes it necessary for regulatory professionals to involve reimbursement professionals early in the product planning process and adjust clinical and regulatory strategies— not only to meet FDA’s needs, but to also ensure that the product will be reimbursed adequately, achieving marketplace success.

Rosina  Robinson of MDCI is expected to comment on how regulatory strategies have changed over the last 5 years. In Europe, a 2007 Medical Device Directive reinforces the need of clinical data, yet even with that amendment that took effect last year, it has been a less difficult route to approval and reimbursement compared the  510 k process in the United States.

Rod Barnes has been performing global studies involving pharmaceuticals and medical devices for the last 13 years and will discuss his experience with devices getting reimbursement in the US faster than in Europe, a rarity.

The panel will meet Thursday June 23rd at the historical Roosevelt Hotel. For more information, click here.

 

TAGGED:healthcare businessmedical technology
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare volunteer communication as a two-way, coordinator-supported process for confirming schedu
How to Manage Volunteer Communication in Healthcare: 5 Tactical Steps and Software Options
Global Healthcare
November 18, 2026
The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026

You Might also Like

Hospital Administration

Was Granny Sent Home from the Hospital Too Soon?

December 14, 2015

Stop Blaming the Patient and Fix the Real Problem – Poor Physician-Patient Communications

December 8, 2013
Finance

An Important Guide To Budgeting For Doctor Appointments

March 12, 2020
FutureMed
Medical DevicesMedical InnovationsTechnology

FutureMed 2013

November 18, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?